Sanli Pharmaceutical released its 2026 interim report. Total operating revenue was 559 million yuan, down 20.31% from the same period last year. Net profit attributable to the parent company was 37.181 million yuan, down 55.24% year-on-year. Net cash inflow from operating activities was 111 million yuan. The asset-liability ratio was 40.21%, gross margin was 71.24%, return on equity was 2.53%, and diluted earnings per share was 0.09 yuan. The company had 18,700 shareholders, and the top ten shareholders held 61.52% of total share capital.
Guizhou Sanli Pharmaceutical Co LtdNet profit fell 55.24% year-on-year, revenue down 20.31%
